The global pulmonary fibrosis biomarkers market is on a strong upward trajectory, with projections indicating an increase from USD 4,353.0 million in 2024 to USD 6,538.4 million by 2034. This anticipated growth reflects a compound annual growth rate (CAGR) of 4.4% over the next decade, building on a valuation of USD 4,149.0 million in 2023.
The market expansion is driven by advancements in pulmonary fibrosis biomarkers, which are making it easier to discover, validate, and integrate new biomarkers into clinical practice. These developments are pivotal in improving the diagnosis and management of pulmonary fibrosis, a chronic and progressive lung disease.
Key factors contributing to market growth include the application of bioinformatics tools and the advancement of high-throughput screening techniques. These innovations enhance the ability to identify and analyze biomarkers with greater precision, leading to more effective and targeted treatments for pulmonary fibrosis.
Get your PDF – Sample Report
The market for pulmonary fibrosis biomarkers is expected to rise, which highlights how the field of pulmonary fibrosis research and clinical practice is changing. Dependable biomarkers will be in greater demand as the prevalence of pulmonary fibrosis rises, driven by factors including aging populations and environmental exposures.
Pulmonary fibrosis biomarkers are crucial for monitoring therapy response and disease activity because they enable clinicians to assess the effectiveness of medications, modify course, and monitor the disease over time. Maintaining patient care and evaluating the efficacy of treatment need long-term monitoring.
Key Takeaways:
- Accelerated Growth: Sales of pulmonary fibrosis biomarkers are projected to accelerate at a CAGR of 4.4% from 2024 to 2034, indicating robust market expansion.
- Market Projection: The market is expected to increase from US$ 4,353.0 million in 2024 to US$ 6,538.4 million by 2034, reflecting growing demand and advancements in biomarker technologies.
- Critical Role: Pulmonary fibrosis biomarkers play a vital role in the diagnosis, prognosis, and treatment monitoring of pulmonary fibrosis, contributing to improved patient outcomes and quality of life.
Customization Available – Here
Competitive Landscape:
Key pulmonary fibrosis biomarker manufacturers significantly shape the sector’s competitive landscape. Known for its dedication to innovation, Biogen welcomes Veracyte, which is one of the significant pulmonary fibrosis biomarker providers, emphasizing cutting-edge diagnostic solutions.
Galapagos NV offers its advantages to the market, while Genentech, a Roche company, adds its pharmaceutical knowledge. Biocartis and Myriad Genetics are essential in pulmonary fibrosis biomarkers since they offer specific solutions.
These key pulmonary fibrosis biomarker vendors work together to enhance research and development, which supports the market’s general expansion and development for pulmonary fibrosis biomarkers. Their combined efforts highlight the pulmonary fibrosis biomarker industry’s dynamic nature as it continues to tackle the difficulties related to pulmonary fibrosis.
Latest Advancements:
- To provide Oklahomans with the newest diagnostic and therapeutic equipment, O.U. Health, a comprehensive academic health system, and Siemens Healthineers, a leader in medical technology, announced a strategic 10-year value partnership in December 2023.
- Thermo Fisher Scientific and AstraZeneca collaborated in January 2023 to create a companion diagnostic test for Tagrisso based on solid tissue and blood. With its global presence, Thermo Fisher Scientific can service a wide range of clients and take advantage of expansion prospects worldwide.
- A deal to buy all of the outstanding shares of Curiosity Diagnostics from Scope Fluidics, S.A., was announced by Bio-Rad Laboratories, Inc. in August 2022. The deal could be worth up to US$ 170 million, with roughly US$ 100 million going toward cash and another US$ 70 million coming from future milestone payments.
- Biogen Inc. agreed to pay a total of US$ 900 million in September 2022 to settle allegations that it gave doctors payments to persuade them to prescribe Biogen drugs, which resulted in the doctors making false claims with Medicare and Medicaid.
Key Players:
- Biogen
- Veracyte
- Genentech (Roche)
- Galapagos NV
- Biocartis
- Myriad Genetics
Key Developments in the Pulmonary Fibrosis Biomarkers Market:
- In September 2022, Biogen Inc. has consented to pay a total of US$ 900 million to resolve claim that it paid kickbacks to doctors to encourage them to prescribe Biogen medications, which led to the filing of false claims with Medicare and Medicaid.
Segmentation Analysis of the Pulmonary Fibrosis Biomarkers Market:
By Test Type:
- HRCT Scans
- X-Ray Scans
- Lung Biopsy
- Blood Tests
- Pulmonary Function Tests
By End User:
- Diagnostic Laboratories
- Academic and Research Institutes
- Hospital Laboratories
- Biopharmaceutical Companies
- Others
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East & Africa
Secure Your Market Analysis Now – Purchase Now to Access
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube